Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent Studies

医学 多发性骨髓瘤 耐火材料(行星科学) 肿瘤科 内科学 天体生物学 物理
作者
Philippe Moreau,María‐Victoria Mateos,Hartmut Goldschmidt,María Esther González García,Britta Besemer,Marta Sonia González,Mohamad Mohty,Joanne Lindsey-Hill,Suriya Kirkpatrick,Michel Delforge,Emanuele Angelucci,Francesco Di Raimondo,Ravi Vij,Margaret Doyle,Kathleen S Gray,Claire Albrecht,Vadim Strulev,Imène Haddad,Silva Koskinen,Lorenzo Acciarri
出处
期刊:Clinical Lymphoma, Myeloma & Leukemia [Elsevier BV]
卷期号:25 (9): 646-655.e1 被引量:18
标识
DOI:10.1016/j.clml.2025.03.014
摘要

BACKGROUND: Patients with relapsed/refractory multiple myeloma (RRMM) who develop extramedullary disease (EMD) generally have a poor prognosis, highlighting the urgent need for new therapies. We report effectiveness outcomes and safety in patients with and without EMD from the pooled analysis of LocoMMotion and MoMMent. METHODS: LocoMMotion and MoMMent-1 are prospective, noninterventional, consecutive studies assessing the evolving standard of care from 20192022 in patients with triple-class exposed RRMM. RESULTS: Of 302 patients, 29 had EMD per investigator discretion and only 15 patients were assessed as having true extramedullary plasmacytoma (EMP; defined as patients with ≥1 EMP lesion) by the response review committee. The 29 EMD patients received 21 unique regimens (most commonly chemotherapy-based regimens). Of the 29 patients with EMD, overall response rate (ORR) was 24.1%, median progression-free survival (PFS) was 2.66 months, median overall survival (OS) was 7.16 months, and median time to next treatment (TTNT) was 3.09 months. All responses were lower (ORR) and shorter (median PFS, OS, and TTNT) in patients with EMD vs patients without EMD. Nineteen (65.5%) patients with EMD received ≥1 subsequent lines of therapy. Of those, two (10.5%) patients received bispecific antibodies and achieved a partial response or better; three (15.8%) patients received antibody-drug conjugates (responses were unknown or not determined at data cut-off), and no patients received chimeric antigen receptorT cell therapy. CONCLUSIONS: These results demonstrate the urgent need for more effective novel therapies for patients with EMD and highlight the need to use clear definitions of EMD and EMD response criteria for clinical trials.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
4秒前
drleslie完成签到 ,获得积分10
5秒前
Alexlovar发布了新的文献求助30
6秒前
6秒前
凯旋归来完成签到 ,获得积分10
6秒前
6秒前
7秒前
zhanzhanzhan发布了新的文献求助20
7秒前
8秒前
路小雨发布了新的文献求助10
9秒前
蒋莹萱完成签到 ,获得积分10
9秒前
简单的浩然完成签到,获得积分10
10秒前
10秒前
10秒前
wangyuu关注了科研通微信公众号
10秒前
活力孤菱完成签到,获得积分10
11秒前
nxdr发布了新的文献求助10
12秒前
英姑的应助被曾经的路灯采纳,获得10
12秒前
dxt发布了新的文献求助10
12秒前
卡皮巴拉完成签到 ,获得积分10
13秒前
GTR的我完成签到 ,获得积分10
13秒前
等风归发布了新的文献求助10
14秒前
Xy完成签到,获得积分10
14秒前
yu发布了新的文献求助10
14秒前
Akim的应助被饼饼采纳,获得10
15秒前
彭于晏的应助被unicornmed采纳,获得10
15秒前
复杂的悟空完成签到,获得积分10
15秒前
Alexlovar完成签到,获得积分20
16秒前
18秒前
Alicyclobacillus完成签到,获得积分10
19秒前
我爱科研科研爱我完成签到,获得积分10
22秒前
23秒前
小蘑菇的应助被陈小黑采纳,获得10
23秒前
24秒前
ly完成签到,获得积分10
24秒前
25秒前
ref:rain完成签到 ,获得积分10
26秒前
杨淼发布了新的文献求助10
27秒前
饼大王完成签到,获得积分10
28秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571584
关于积分的说明 21818707
捐赠科研通 7778124
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557710
邀请新用户注册赠送积分活动 2479621